Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 interventional single arm study describing platelet responses and ITP remission rates in adult subjects with immune thrombocytopenia purpura receiving romiplostim

Next Previous
Trial Profile

A phase 2 interventional single arm study describing platelet responses and ITP remission rates in adult subjects with immune thrombocytopenia purpura receiving romiplostim

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Sponsors Amgen

Most Recent Events

  • 14 Dec 2021 Results of subgroup analysis presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 01 Jun 2020 Results of integrated analysis of five clinical trials evaluating the efficacy and safety of romiplostim self-administration published in the American Journal of Hematology
  • 18 Oct 2019 According to an Amgen media release, based on the results of this trial, the U.S. FDA has approved romiplostim for an additional indication of treatment of newly diagnosed and persistent adult Idiopathic-thrombocytopenic-purpura patients who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top